On March 14, 2019 Elpiscience Biopharma, Ltd. reported its first Symposium on "Novel Targets for Cancer Immunotherapy", which will be held on March 24th, at Shanghai Kempinski Hotel (Press release, Elpiscience, MAR 14, 2019, View Source;id=1310 [SID1234536919]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The field of Cancer Immunotherapy is advancing in a breathtaking speed. The first generation of immune check point antibodies such as PD1/PD-L1, CTLA4 antibodies have revolutionized clinical practice in many cancer types. However a majority of cancer patients can still not benefit from the first generation of IO drugs. Novel targets and innovative approaches are in urgent demand to meet the unmet medical needs. The symposium brings together world leaders in immuno-oncology, to explore new therapeutic targets and approaches, to inspire and open up game-changing paths for the next generation of cancer immunotherapies.